Cardiovascular Therapeutics
2.315
Current Impact Factor
2.315
Current Impact Factor
109
Days
Average time from submission to acceptance
43
Days
Average time from acceptance to publication
Most Viewed Articles
| Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy After Recent Ischemic Stroke: A Systematic Review and Meta-analysis | 4,886 |
| Dual antiplatelet therapy duration in acute coronary syndrome patients: the state of the art and open issues | 1,996 |
| Burden of coronary artery disease and peripheral artery disease: A literature review | 1,845 |
| Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials | 1,288 |
| Comparison of the effect of fimasartan vs. valsartan on blood pressure variability in acute ischemic stroke: A double-blind randomised trial | 1,131 |
| Safety and tolerability of initiating maximum dose sacubitril-valsartan in patients on target dose renin-angiotensin system inhibitors | 1,071 |
| Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries | 1,061 |
| Long-term prognosis of suspected myocarditis and cardiomyopathy associated with viral infection of the myocardial tissue: a meta-analysis of cohort studies | 1,052 |
| Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials | 1,048 |
| Sex-specific Cut-offs For High-sensitivity Cardiac Troponin: Is Less More? | 1,044 |
Most Viewed Special Issue Articles
The Wiley Hindawi Partnership
Cardiovascular Therapeutics is a Wiley Hindawi Partnership Title. Click here for more information.
